

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

					Complete ij Known		
Substitute for form 1449A/PTO INFORMATION DISCLOSURE				Application Number	10/65	9,747	
				Filing Date	Septe	mber 11, 2003	
ST	STATEMENT BY APPLICANT				First Named Inventor	Alexa	ander LEVITZKI et al
	(use as many sheets as necessary)			Art Unit	1618		
			•		Examiner Name	JONE	S, DAMERON LEVEST
Sheet	1		of	2	Attorney Docket Number	26682	2
			U.S.	PATENT	DOCUMENTS		
Examiner Cite Initials* No. 1		Document Number	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	-	Number-Kind Code ^{2 (if known)}					rigures repress
400	1	US-6,251,912	06-26-2	001	Wissner et al.		
7		US-5,760,041	02-2-1998		Wissner et al.		
1,1		US-6,153,617	11-28-2000 Bridges				
		US-6,127,374	03-3-20				
	5	US-2002/0128553	09-12-2	002	Mishani et al.		
70							
							
	\perp	<u></u>					
			<u> </u>				
	\perp						
	_						
	-		<u> </u>				· · · · · · · · · · · · · · · · · · ·
		-	 				
1	L						

		FOREIGN	PATENT DOC	UMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ¹ Number ⁴ Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
10	6	PCT WO 02/073235	09-19-2002	Levitzki et al.		
1.7	7	PCT WO 2005/023315	03-17-2005	Mishani et al.		Ш
11/	8	PCT WO 99/09016	02-25-1999	Wissner et al.		
7	9	PCT WO 2004/046101	03-3-2004	Wallace et al.		Ш
						Ш
···········		\sim				\sqcup
Examine Signature		0000		Date Considered	2/16/06	7

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

quired to respond to a collection of information unless it contains a valid OMB control number.

Under the Paper	work Reduction	Act of 1995, no PAOLE The required to respond to a c	offection of information un	Complete	f Known	
	Sub	stitute for form 1449A/PTO	Application Number	10/659,747		
ł	TAIR	DRMATION DISCLOSUR	Filing Date	September 11, 2003		
			First Named Inventor	Alexander LEVITZKI		
[STA	TEMENT BY APPLICAN	ľ		et al	
1		(use as many sheets as necessary)	Group Art Unit 1618			
	,	ase as many sneeds as necessary)		Examiner Name	JONES, DAMERON LEVEST	
\				Attorney Docket Number		
Sheet	2	Of OTHER PRIOR ARE NO	12		20082	
		OTHER PRIOR ART – NON Include name of the author (in CAPITAL L	PATENT LITER	ATURE DUCUMENTS	of the	
Examiner Initials	Cite No.1	item (book, magazine, journal, serial symp	osium, catalog, etc.) da and/or country where p	ite, page(s), volume-issue numb	er(s), T^2	
		Smaill et al. "Tyrosine Kinase Inhib	itors 17 Irrayarsil	ole Inhibitors of the Enide	ermal	
	10	Growth Factor Receptor: 4-(Phenyla	mina)()uinazaline	ne minoriors of the Lpice	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
1 M	-1)	(Phenylamino)Pyrido[3,2-d]Pyrimid	lina-6-A caylamide	s Rearing Additional		
'	y	Solubilizing Functions", Journal of	Medicinal Chemics	bry 43. 1380-1397 2000		
	∕	Compound 18, 25-27, Table 1.				
	11	Smaill et al. "Tyrosine Kinase Inhib	itors. 15. 4-(Pheny	lamino)Quiazoline and 4	-	
1 1	1	(Phenylamino)Pyrido[d]Pyrimidine	Acrylamides as Iri	reversible Inhibitors of the	e ATP	
1 1		Binding Site of the Epidermal Grow	th Factor Receptor	r", Journal of Medicinal		
]		Chemistry, 42: 1802-1815, 1999.				
	12	Mishani et al. "Carbon-11 Labeling				
		(Phenylamino)-Quinazolin-6-Yl]-A	mides, A New Clas	ss of EGFR Irreversible	i	
l I		Inhibitors", Journal of Labelled Con	npounds and Radio	opharmaceuticals, 46(S1)	: S2,	
1 1	- 1	2003. Abstract.				
	13	Ortu et al. "Labeled EGFR-TK Irrev	ersible Inhibitor (l	ML03) In Vitro and In Vi	vo	
}	· I	Properties, Potential as Pet Biomark	er for Cancer and	Feasibility as Anticancer		
1		Drug", International Journal of Can	cer, 101: 360-370,	2002. Conclusion, P.361,	,	
		Col.1, § 1, Fig.1.				
	14	Johnström et al. "Synthesis of [Metl	10xy-11C]PD1530	35, A Selective EGF Rec	eptor	
1		Tyrosine Kinase Inhibitor", Journal				
		Radiopharmaceuticals, XLI: 623-62	9, 1998. P.627, Fi	g.3.		
11/	15	Mishani et al. "Novel Carbon-11 La	beled 4-Dimethyla	amino-But-2-Enoic Acid	[4-	
1	۱ ((Phenylamino)-Quinazoline-6-Yl]-A	Amides: Potential I	PET Bioprobes for Molec	cular	
1 NO	11	Imaging of EGFR-Positive Tumors	', Nuclear Medicin	ne and Biology, 31(4): 46	9-476,	
		2004. P.474, Col.2, § 4 - P.475, Fig	s.2, 3.			
			· · · · · · · · · · · · · · · · · · ·			

Signature

Considered

^{*}EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with fiext communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.